- Home
- PRVA vs MIRM Comparison
PRVA vs MIRM Comparison
Compare PRVA & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRVA
- MIRM
- Stock Information
- Founded
- PRVA 2007
- MIRM 2018
- Country
- PRVA United States
- MIRM United States
- Employees
- PRVA N/A
- MIRM N/A
- Industry
- PRVA Retail: Computer Software & Peripheral Equipment
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- PRVA Technology
- MIRM Health Care
- Exchange
- PRVA Nasdaq
- MIRM Nasdaq
- Market Cap
- PRVA 3.1B
- MIRM 3.7B
- IPO Year
- PRVA 2021
- MIRM 2019
- Fundamental
- Price
- PRVA $24.44
- MIRM $73.39
- Analyst Decision
- PRVA Strong Buy
- MIRM Strong Buy
- Analyst Count
- PRVA 14
- MIRM 11
- Target Price
- PRVA $28.64
- MIRM $76.09
- AVG Volume (30 Days)
- PRVA 990.3K
- MIRM 841.8K
- Earning Date
- PRVA 11-06-2025
- MIRM 11-11-2025
- Dividend Yield
- PRVA N/A
- MIRM N/A
- EPS Growth
- PRVA N/A
- MIRM N/A
- EPS
- PRVA 0.11
- MIRM N/A
- Revenue
- PRVA $1,900,071,000.00
- MIRM $429,161,000.00
- Revenue This Year
- PRVA $96.90
- MIRM $53.14
- Revenue Next Year
- PRVA $1.02
- MIRM $19.83
- P/E Ratio
- PRVA $219.50
- MIRM N/A
- Revenue Growth
- PRVA 12.05
- MIRM 62.33
- 52 Week Low
- PRVA $17.36
- MIRM $36.88
- 52 Week High
- PRVA $26.09
- MIRM $78.55
- Technical
- Relative Strength Index (RSI)
- PRVA 59.96
- MIRM 54.61
- Support Level
- PRVA $23.72
- MIRM $71.43
- Resistance Level
- PRVA $24.87
- MIRM $78.54
- Average True Range (ATR)
- PRVA 0.67
- MIRM 2.29
- MACD
- PRVA -0.06
- MIRM -0.55
- Stochastic Oscillator
- PRVA 55.02
- MIRM 36.02
About PRVA Privia Health Group Inc.
Privia Health Group Inc is a technology-driven, national physician-enablement company. It collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual care settings.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.